Clinical and epidemiological correlates of antibody response to human papillomaviruses (HPVs) as measured by a novel ELISA based on denatured recombinant HPV16 late (L) and early (E) antigens

被引：6

作者：

Giorgi C. ^{[1
]}

Di Bonito P. ^{[1
]}

Grasso F. ^{[1
]}

Mochi S. ^{[1
]}

Accardi L. ^{[1
]}

Donà M.G. ^{[1
]}

Branca M. ^{[2
]}

Costa S. ^{[3
]}

Mariani L. ^{[4
]}

Agarossi A. ^{[5
]}

Ciotti M. ^{[6
]}

Syrjänen K. ^{[7
]}

Leoncini L. ^{[2
]}

Alderisio M. ^{[2
]}

Santini D. ^{[3
]}

De Nuzzo M. ^{[3
]}

Di Bonito L. ^{[8
]}

Bonifacio D. ^{[8
]}

Zanconati F. ^{[8
]}

Galati M. ^{[9
]}

Sesti F. ^{[10
]}

Piccione E. ^{[10
]}

Criscuolo A. ^{[10
]}

Benedetto A. ^{[6
]}

Paba P. ^{[6
]}

Favalli C. ^{[6
]}

Casolati E.A. ^{[5
]}

Valieri M. ^{[5
]}

Di Carlo A. ^{[11
]}

HPV-PathogenISS group

机构：

[1] Department of Infectious, Parasitic and Immunomediated Diseases, Istituto Superiore di Sanità, Roma

[2] Unità Citoistopatologia, Centro Nazionale di Epidemiologia, Sorveglianza e Promozione della Salute, Istituto Superiore di Sanità, Roma

[3] Dipartimento di Ginecologia e Ostetricia, Ospedale S. Orsola Malpighi, Bologna

[4] Clinica Ostetrica e Ginecologica, IFO, Istituto Regina Elena, Roma

[5] Istituto Scienze Biomediche, Ospedale Luigi Sacco, Clinica Ostetrica e Ginecologica, Milano

[6] Laboratory of Clinical Microbiology and Virology, Policlinico of Tor Vergata University, Rome

[7] Department of Oncology and Radiotherapy, Turku University Hospital, Turku

[8] U.C.O. Anatomia Patologica, Istopatologia e Citodiagnostica, Ospedale Maggiore, Trieste

[9] Dipartimento di Ginecologia e Ostetricia, IFO, Istituto Regina Elena, Roma

[10] Isituto di Ginecologia, Università di Tor Vergata, Roma

[11] Unità Operativa MST/HIV, IFO, Istituto San Gallicano, Roma

来源：

Infectious Agents and Cancer | / 3卷 / 1期

关键词：

Cervical Carcinoma; Serological Response; Avidity Index; Recombinant HPV16; High Avidity Index;

D O I：

10.1186/1750-9378-3-9

中图分类号：

学科分类号：

摘要：

Background: At present, seroreactivity is not a valuable parameter for diagnosis of Human Papillomavirus (HPV) infection but, it is potentially valuable as marker of viral exposure in elucidating the natural history of this infection. More data are needed to asses the clinical relevance of serological response to HPV. Objectives: The objective was to assess the clinical and epidemiological correlates of HPVseroreactivity in a cohort of HIV-negative and HIV-positive women. Methods: Seroreactivity of 96 women, evaluated in an ELISA test based on denatured HPV16 late (L) and early (E) antigens, was correlated with their clinical and epidemiological data previously collected for a multi-centre Italian study, HPV-PathogenISS study. Results: No significant correlation was found between HPV DNA detection and seroreactivity. Women, current smokers showed significantly less seroreactivity to L antigens as compared with the non-smokers. HIV-positive women showed significantly less (66.7%) antibody response as compared with HIV-negative women (89.3%), with particularly impaired response to L antigens. Women, HIV-positive and current smokers, showed by far the lowest seroprevalence (33.3%) as compared to 75.9%among all other women (OR=0.158; 95%CI 0.036-0.695, p=0.014; Fisher's exact test). Importantly, this association did not loose its significance when controlled for confounding from age (continuous variable) in multivariate analysis or using Mantel-Haenszel test for age-groups. Conclusion: It is tempting to speculate that HIV-positive current smokers comprise a special highrisk group, with highly impaired immunological response that could prevent eradication of persistent HPV infections and thus contribute to development of CIN3/CC. © 2008 Giorgi et al; licensee BioMed Central Ltd.

引用

共 52 条

[1]

Syrjanen K., Syrjanen S., Papillomavirus Infections in Human Pathology, pp. 1-615, (2000)

[2]

Campo S., Papillomavirus Research: From Natural History to Vaccines and Beyond, pp. 1-424, (2006)

[3]

Munoz N., Bosch F.X., De Sanjose S., Herrero R., Castellsague X., Shah K.V., Snijders P.J., Meijer C.J., Epidemiologic classification of human papillomavirus types associated with cervical cancer, N Engl J Med, 348, pp. 518-527, (2003)

[4]

Cliffort G.M., Gallus S., Herrero R., Munoz N., Snijders P.J.F., Vaccarella S., Anh P.T.H., Ferreccio C., Hieu N.T., Matos E., Molano M., Rajkumar R., Ronco G., De Sanjose S., Shin H.R., Sukvirach S., Thomas J.O., Tunsakul S., Cjlm M., Franceschi S., Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for research on Cancer HPV prevalence surveys: Pooled analysis, Lancet, 366, pp. 991-998, (2005)

[5]

Monsonego J., Bohbot J.M., Pollini G., Krawec C., Vincent C., Merignargues I., Haroun F., Dachez R., Syrjanen K., Performance of the ROCHE AMPLICOR® Human Papillomavirus (HPV) test in detection of cervical intraepithelial neoplasia (CIN) in management of women with abnormal PAP smear, Gynecol Oncol, 99, pp. 160-168, (2005)

[6]

Lorincz A.T., Richart R.M., Human papillomavirus DNA testing as an adjunct to cytology in cervical screening programs, Arch Pathol Lab Med, 127, pp. 959-968, (2003)

[7]

Monographs on the evaluation of carcinogenic risks to humans. Human Papillomaviruses, IARC, Lyon, 64, pp. 1-409, (1995)

[8]

Pyrhonen S., Penttinen K., Wart virus antibodies and the prognosis of wart disease, Lancet, 2, 7791, pp. 1330-1332, (1972)

[9]

Kirnbauer R., Booy F., Cheng N., Lowy D.R., Schiller J.T., Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic, Proc Natl Acad Sci USA, 89, pp. 12180-12184, (1992)

[10]

Galloway D.A., Papillomavirus capsids: A new approach to identify serological markers of HPV infection, J Natl Cancer Inst, 86, pp. 474-475, (1994)

← 1 2 3 4 5 6 →